Ghent University Academic Bibliography

Your filters: cql: author="Deodhar, Atul" or (type any "bookEditor issueEditor" and editor="Deodhar, Atul")

Add to list
- Journal Article
- A1
- open access
Etanercept withdrawal and retreatment in nonradiographic axial spondyloarthritis : results of RE-EMBARK, an open-label phase IV trial

Filip Van den Bosch (UGent) , James Cheng-Chung Wei, Peter Nash, Francisco J. Blanco, Daniela Graham, Chuanbo Zang, Edmund Arthur, Cecilia Borlenghi, Vassilis Tsekouras, Bonnie Vlahos, et al.

(2023) JOURNAL OF RHEUMATOLOGY. 50(4). p.478-487
Add to list
- Journal Article
- A1
- open access
Efficacy and safety of bimekizumab in axial spondyloarthritis : results of two parallel phase 3 randomised controlled trials

Desiree van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A. Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut (UGent) , Alicia M. Ellis, Carmen Fleurinck, Karl Gaffney, et al.

(2023) ANNALS OF THE RHEUMATIC DISEASES. 82(4). p.515-526
Add to list
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2) : a randomised, double-blind, placebo-controlled, phase 3 trial

Atul Deodhar, Filip Van den Bosch (UGent) , Denis Poddubnyy, Walter P Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, et al.

(2022) LANCET. 400(10349). p.369-379
Add to list
- Journal Article
- A1
- open access
Upadacitinib in active ankylosing spondylitis : results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

Desiree van der Heijde, Atul Deodhar, Walter P. Maksymowych, Joachim Sieper, Filip Van den Bosch (UGent) , Tae-Hwan Kim, Mitsumasa Kishimoto, Andrew J. Ostor, Bernard Combe, Yunxia Sui, et al.

(2022) RMD OPEN. 8(2).
Add to list
- Journal Article
- A1
- open access
Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis : pooled analysis of two phase 3 studies

Xenofon Baraliakos, Filip Van den Bosch (UGent) , Pedro M. Machado, Lianne S. Gensler, Helena Marzo-Ortega, Bintu Sherif, Erhard Quebe-Fehling, Brian Porter, Corine Gaillez and Atul Deodhar

(2021) RHEUMATOLOGY AND THERAPY. 8(1). p.273-288
Add to list
- Journal Article
- A1
- open access
Secukinumab efficacy on enthesitis in patients with ankylosing spondylitis : pooled analysis of four pivotal phase III studies

Georg Schett, Xenofon Baraliakos, Filip Van den Bosch (UGent) , Atul Deodhar, Mikkel Ostergaard, Ayan Das Gupta, Shephard Mpofu, Todd Fox, Adam Winseck, Brian Porter, et al.

(2021) JOURNAL OF RHEUMATOLOGY. 48(8). p.1251-1258
Add to list
- Journal Article
- A1
- open access
Secukinumab in non-radiographic axial spondyloarthritis : subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Jurgen Braun, Ricardo Blanco, Helena Marzo-Ortega, Lianne S. Gensler, Filip Van den Bosch (UGent) , Stephen Hall, Hideto Kameda, Denis Poddubnyy, Marleen van de Sande, Anna S. Wiksten, et al.

(2021) ARTHRITIS RESEARCH & THERAPY. 23(1).
Add to list
- Journal Article
- A1
- open access
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Maxime Dougados, James Cheng-Chung Wei, Robert Landewe, Joachim Sieper, Xenofon Baraliakos, Filip Van den Bosch (UGent) , Walter P. Maksymowych, Joerg Ermann, Jessica A. Walsh, Tetsuya Tomita, et al.

(2020) ANNALS OF THE RHEUMATIC DISEASES. 79(2). p.176-185
Add to list
- Journal Article
- A1
- open access
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis : 5-year results from the phase III MEASURE 1 extension study

Xenofon Baraliakos, Juergen Braun, Atul Deodhar, Denis Poddubnyy, Alan Kivitz, Hasan Tahir, Filip Van den Bosch (UGent) , Evie-Maria Delicha, Zsolt Talloczy and Anke Fierlinger

(2019) RMD OPEN. 5(2).
Add to list
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1) : a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Desiree van der Heijde, In-Ho Song, Aileen L Pangan, Atul Deodhar, Filip Van den Bosch (UGent) , Walter P Maksymowych, Tae-Hwan Kim, Mitsumasa Kishimoto, Andrea Everding, Yunxia Sui, et al.

(2019) LANCET. 394(10214). p.2108-2117

Academic Bibliography

Etanercept withdrawal and retreatment in nonradiographic axial spondyloarthritis : results of RE-EMBARK, an open-label phase IV trial

Efficacy and safety of bimekizumab in axial spondyloarthritis : results of two parallel phase 3 randomised controlled trials

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2) : a randomised, double-blind, placebo-controlled, phase 3 trial

Upadacitinib in active ankylosing spondylitis : results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis : pooled analysis of two phase 3 studies

Secukinumab efficacy on enthesitis in patients with ankylosing spondylitis : pooled analysis of four pivotal phase III studies

Secukinumab in non-radiographic axial spondyloarthritis : subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis : 5-year results from the phase III MEASURE 1 extension study

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1) : a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Contents

Support

Contact